{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:36:31Z","timestamp":1773308191944,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/mpa.0000000000000202","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T14:15:27Z","timestamp":1406643327000},"page":"99-105","source":"Crossref","is-referenced-by-count":7,"title":["Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue"],"prefix":"10.1097","volume":"44","author":[{"given":"Stephanie","family":"Booy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Marlijn","family":"Waaijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Croze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"van Koetsveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette","family":"de Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper H.J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-13-20210212","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-13-20210212","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijc.20236","article-title":"Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors.","volume":"111","author":"Wagner","year":"2004","journal-title":"Int J Cancer"},{"key":"R4-13-20210212","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ejca.2011.03.009","article-title":"Type I interferons as radiosensitisers for pancreatic cancer.","volume":"47","author":"Morak","year":"2011","journal-title":"Eur J Cancer"},{"key":"R5-13-20210212","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/1359-6101(96)00017-2","article-title":"The type-I interferon receptor. The long and short of it.","volume":"7","author":"Domanski","year":"1996","journal-title":"Cytokine Growth Factor Rev"},{"key":"R6-13-20210212","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9610(03)00051-5","article-title":"Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.","volume":"185","author":"Picozzi","year":"2003","journal-title":"Am J Surg"},{"key":"R7-13-20210212","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/SLA.0b013e318181e4e9","article-title":"Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.","volume":"248","author":"Linehan","year":"2008","journal-title":"Ann Surg"},{"key":"R8-13-20210212","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P","article-title":"A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma.","volume":"83","author":"Brembeck","year":"1998","journal-title":"Cancer"},{"key":"R9-13-20210212","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1245\/s10434-011-1847-4","article-title":"Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.","volume":"18","author":"Katz","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R10-13-20210212","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/annonc\/mdq384","article-title":"Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.","volume":"22","author":"Picozzi","year":"2011","journal-title":"Ann Oncol"},{"key":"R11-13-20210212","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0959-8049(01)00319-7","article-title":"Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.","volume":"38","author":"Wagener","year":"2002","journal-title":"Eur J Cancer"},{"key":"R12-13-20210212","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","article-title":"Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.","volume":"30","author":"Schmidt","year":"2012","journal-title":"J Clin Oncol"},{"key":"R13-13-20210212","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00268-006-0561-z","article-title":"Differences between ampullary, periampullary and pancreatic cancer.","volume":"31","author":"Fisher","year":"2007","journal-title":"World J Surg"},{"key":"R14-13-20210212","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/bjs.8734","article-title":"Resection margin involvement and tumour origin in pancreatic head cancer.","volume":"99","author":"Verbeke","year":"2012","journal-title":"Br J Surg"},{"key":"R15-13-20210212","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/SLA.0b013e318190c53e","article-title":"Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.","volume":"248","author":"Morak","year":"2008","journal-title":"Ann Surg"},{"key":"R16-13-20210212","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/0008-5472.CAN-05-3043","article-title":"IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.","volume":"66","author":"Vitale","year":"2006","journal-title":"Cancer Res"},{"key":"R17-13-20210212","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"key":"R18-13-20210212","first-page":"716","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"R19-13-20210212","first-page":"187","article-title":"Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors.","volume":"5","author":"Kaemmerer","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"R20-13-20210212","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","article-title":"Molecular imaging with (6)(8)Ga-SSTR PETCT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.","volume":"38","author":"Kaemmerer","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-13-20210212","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.sla.0000261460.07110.f2","article-title":"Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.","volume":"246","author":"Vitale","year":"2007","journal-title":"Ann Surg"},{"key":"R22-13-20210212","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev.bi.56.070187.003455","article-title":"Interferons and their actions.","volume":"56","author":"Pestka","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"R23-13-20210212","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001622-200311000-00005","article-title":"Interferons: mechanisms of action and clinical applications.","volume":"15","author":"Parmar","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"R24-13-20210212","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/jir.2010.0158","article-title":"Interferon: current status and future prospects in cancer therapy.","volume":"31","author":"Wang","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"R25-13-20210212","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.yexcr.2011.03.002","article-title":"Beta-interferon for multiple sclerosis.","volume":"317","author":"Rudick","year":"2011","journal-title":"Exp Cell Res"},{"key":"R26-13-20210212","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/08977190400000833","article-title":"Human interferons alpha, beta and omega.","volume":"22","author":"Bekisz","year":"2004","journal-title":"Growth Factors"},{"key":"R27-13-20210212","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-2407-9-160","article-title":"A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survivalCapRI-2.","volume":"9","author":"Marten","year":"2009","journal-title":"BMC Cancer"},{"key":"R28-13-20210212","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1872-034X.2007.00007.x","article-title":"Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells.","volume":"37","author":"Damdinsuren","year":"2007","journal-title":"Hepatol Res"},{"key":"R29-13-20210212","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/jcmm.12200","article-title":"Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells.","volume":"18","author":"Booy","year":"2014","journal-title":"J Cell Mol Med"},{"key":"R30-13-20210212","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ejso.2012.07.113","article-title":"Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer.","volume":"38","author":"Pomianowska","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"R31-13-20210212","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1.","volume":"14","author":"de Weerd","year":"2013","journal-title":"Nat Immunol"},{"key":"R32-13-20210212","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2009.10.013","article-title":"Redefining the role of interferon in the treatment of malignant diseases.","volume":"46","author":"Bracarda","year":"2010","journal-title":"Eur J Cancer"},{"key":"R33-13-20210212","first-page":"249","article-title":"Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.","volume":"16","author":"Ota","year":"2006","journal-title":"Oncol Rep"},{"key":"R34-13-20210212","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.surg.2005.11.010","article-title":"Expression of interferon receptors in pancreatic cancer: identification of a novel prognostic factor.","volume":"139","author":"Saidi","year":"2006","journal-title":"Surgery"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000000202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:11:53Z","timestamp":1620965513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201501000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000000202","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}